PASG
Passage Bio Inc
1 day chart
About PASG
Passage Bio, Inc. is a clinical stage genetic medicines company. The Company is focused on developing transformative therapies for central nervous system (CNS) disorders. Its first product candidate, PBGM01, utilizes a AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (ß-gal), for GM1. Its second product candidate, PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), for FTD caused by progranulin deficiency (FTD-GRN). Its third product candidate, PBKR03, utilizes a next-generation AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosyl ceramidase, (GALC) for Krabbe disease. The Company also has six programs in the research stage: PBML04 for metachromatic leukodystrophy; PBAL05 for amyotrophic lateral sclerosis; PBCM06 for Charcot-Marie-Tooth Type 2A; and programs for Canavan disease, and others.
Buy US stocks in Australia with $0 brokerage and trade PASG today!
$66.45M
-
0.00%
93.27K
$1.37
$1.21
$1.25
$10.37
$1.20
Related Stocks
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.